Wedbush Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
I'm PortAI, I can summarize articles.
Wedbush analyst Martin Fan maintained a Buy rating on Aclaris Therapeutics with a price target of $8.00, while the stock closed at $3.08. Fan, a 4-star analyst with a 41.4% average return, focuses on the Healthcare sector. The general analyst consensus for Aclaris Therapeutics is a Strong Buy with a $9.25 average price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments